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Abstract Aurora kinases have emerged as attractive targets for the design of anticancer 
drugs. 3D-QSAR (comparative molecular field analysis (CoMFA) and comparative 
molecular similarity indices analysis (CoMSIA)) and Surflex-docking studies were 
performed on a series of pyrrole-indoline-2-ones as Aurora A inhibitors. The CoMFA and 
CoMSIA models using 25 inhibitors in the training set gave r
2
cv values of 0.726 and 0.566, 
and r
2 values of 0.972 and 0.984, respectively. The adapted alignment method with the 
suitable parameters resulted in reliable models. The contour maps produced by the CoMFA 
and CoMSIA models were employed to rationalize the key structural requirements 
responsible for the activity. Surflex-docking studies revealed that the sulfo group, 
secondary amine group on indolin-2-one, and carbonyl of 6,7-dihydro-1H-indol-4(5H)-one 
groups were significant for binding to the receptor, and some essential features were also 
identified. Based on the 3D-QSAR and docking results, a set of new molecules with high 
predicted activities were designed. 
Keywords: 3D-QSAR; CoMFA; CoMSIA; Docking; pyrrole-indoline-2-ones;   
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1. Introduction 
The Aurora kinases are a family of highly conserved serine/threonine protein kinases that play a key 
role in regulating many pivotal processes of mitosis and completion of cell division [1–5]. The two 
major Aurora kinases, Aurora A and Aurora B, play distinct roles in mitosis, though they are very 
closely related in kinase domain sequence (71% identical) and have the identical residues lining the 
binding pocket for the ATP adenine ring [6]. Aurora A is involved in centrosome maturation and 
separation, bipolar spindle assembly, and mitotic entry, while Aurora B is essential for accurate 
chromosome segregation and cytokinesis [7]. In recent years, Aurora A and B have been actively 
pursued as anticancer targets for the discovery of new cancer chemotherapeutics [8]. Aurora A has 
especially been identified as a colon-cancer-associated kinase that is overexpressed in a wide range of 
human tumors such as breast, colorectal, ovarian, as well as glioma [9,10]. Thus, targeted inhibition of 
Aurora A has become an attractive therapeutic strategy in cancer therapy, and more than 10 Aurora 
inhibitors have entered early clinical assessment [11,12]. 
A series of pyrrole-indoline-2-ones with Aurora A inhibitory activities were reported [13]. These 
pyrrole-indoline-2-ones, with excellent Aurora A inhibitory activities, were designed and synthesized 
by sharing a similar scaffold with Hesperadin [14]. In the present study, three-dimensional quantitative 
structure-activity relationship (3D-QSAR) methods along with docking approaches were used to 
explore the structure-activity relationship (SAR) of these pyrrole-indoline-2-ones. 3D-QSAR methods, 
comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis 
(CoMSIA), were performed to foresee the activities of these pyrrole-indoline-2-ones and offered the 
regions where interactive fields (steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen 
bond acceptor fields) may increase or decrease the activity. Surflex-Docking was applied to study the 
interactions between 35 pyrrole-indoline-2-ones and Aurora A. These developed models can help 
understanding the SAR of the pyrrole-indoline-2-ones and can also serve as a valuable guide for the 
design of novel inhibitors with robust potency.   
Furthermore, we have designed a number of new pyrrole-indoline-2-ones derivatives by utilizing 
the structure information obtained from the CoMFA and CoMSIA models, which exhibit excellent 
predictive potencies. Moreover, based on the admirable performance of docking studies, the predicted 
activities of these newly designed molecules may be reliable. 
2. Materials and Methods 
2.1. Data Sets 
All of the 35 compounds and associated data involved in this study were obtained from  
literature [13]. The inhibitory activity data were reported as IC50 against Aurora A. The IC50 values 
were converted into pIC50 according to the formula in Equation 1 [15]. In CoMFA and CoMSIA 
models, the dataset was randomly divided into training and test sets including 25 and 10 molecules, 
respectively. The structures of the molecules are shown in Table 1 and associated inhibitory activities 
are shown in Table 2, where pIC50 values for 35 inhibitors ranged from 5.611 to 8.073. 
pIC50 = −Log IC50               ( 1 )  Int. J. Mol. Sci. 2011, 12 
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Table 1. The structures of the training and test set molecules. 
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Table 1. Cont. 
18 
MeHN
S
O2 COOH 
19 
N
S
O2
COOH 
20  N
S
O2
COOH 
21  N
S
O2
COOH 
22  N
S
O2
O
COOH 
23  S
O2
H
N COOH 
24  S
O2
H
N COOH 
25  S
O2
H
N
COOH 
26  S
O2
H
N
COOEt 
27  S
O2
H
N N
O
 
28  S
O2
H
N N
O
O  
29  S
O2
H
N HN
O
 
30 
N
S
O2
N
O
O  
31  S
O2
H
N N
C
H2  
 
 Int. J. Mol. Sci. 2011, 12 
 
1609
Table 1. Cont. 
32  S
O2
H
N N
C
H2  
33  S
O2
H
N
 
N
C
H2  
34 
N
S
O2
N
C
H2  
35 
N
S
O2
N
C
H2  
Table 2. The actual pIC50s, predicted pIC50s (Pred.) and their residuals (Res.) of the 
training and test set molecules. 
Compd. 
No. 
pIC50 CoMFA  CoMSIA 
Actual  Pred. Res. Pred. Res. 
1  5.750 5.775 -0.025 5.703 0.047 
2*  5.703 5.698 0.005 5.819 -0.116 
3  6.682 6.573 0.109 6.512 0.170 
4*  6.750 6.499 0.251 6.628 0.122 
5  6.341 6.372 -0.031 6.510 -0.169 
6*  6.441 6.536 -0.095 6.565 -0.124 
7  6.678 6.602 0.076 6.729 -0.051 
8  6.140 6.473 -0.333 6.175 -0.035 
9  6.447 6.262 0.185 6.403 0.044 
10  6.252 6.211 0.041 6.342 -0.090 
11*  6.599 6.844 -0.245 6.471 0.128 
12  6.143 6.221 -0.078 6.136 0.007 
13*  7.244 7.333 -0.089 7.155 0.089 
14  7.409 7.390 0.019 7.345 0.064 
15  6.567 6.455 0.112 6.498 0.069 
16  6.354 6.347 0.007 6.421 -0.067 
17  7.215 7.209 0.006 7.152 0.063 
18  7.509 7.580 -0.071 7.530 -0.021 
19*  7.678 7.544 0.134 7.566 0.112 
20  8.155 8.073 0.082 8.049 0.106 
21  7.854 7.803 0.051 7.977 -0.123 
22  7.538 7.623 -0.085 7.548 -0.010 
23  7.469 7.715 -0.247 7.623 -0.155 
24  7.921 7.623 0.298 7.751 0.170 Int. J. Mol. Sci. 2011, 12 
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Table 2. Cont. 
25*  7.201 7.545 -0.344 7.449 -0.248 
26  7.076 7.101 -0.025 6.995 0.081 
27  6.662 6.630 0.032 6.806 -0.145 
28*  6.551 6.697 -0.146 6.857 -0.306 
29  6.932 7.030 -0.098 6.880 0.052 
30  6.250 6.303 -0.053 6.350 -0.101 
31*  5.664 5.765 -0.102 5.682 -0.019 
32  5.660 5.621 0.039 5.651 0.009 
33  5.611 5.584 0.027 5.619 -0.008 
34  5.644 5.677 -0.033 5.550 0.094 
35*  5.631 5.660 -0.029 5.466 0.165 
* Test set molecules. 
2.2. Molecular Modeling and Database Alignment 
Molecular modeling and database alignment were performed by using the molecular modeling 
package SYBYL 8.1 Tripos, Inc. [16]. The three-dimensional structures of all pyrrole-indoline-2-ones 
were constructed by using the Sketch Molecule module. Energy minimization of each structure was 
performed using the SYBYL energy minimizer Tripos force field and Gasteiger-Hückel charge. The 
maximum iterations for the minimization was set to 2000. The minimization was terminated when the 
energy gradient convergence criterion of 0.05 kcal/mol·Å was reached [17]. 
Figure 1. Common substructure used for alignment. 
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Figure 2. Alignment of the compounds used in the training set. 
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Molecular alignment was considered as one of the most sensitive parameters in 3D-QSAR  
analyses [18]. The quality and the predictive ability of the model are directly dependent on the 
alignment rule [19]. In this paper, all of the structures were aligned into a lattice box by fitting with 
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one (Figure 1) as a common structure using compound 20 
as a template, which was the most active compound. The aligned molecules are shown in Figure 2. 
2.3. CoMFA and CoMSIA Setup 
CoMFA is a widely used 3D-QSAR method, which relates the biological activity of a series of 
molecules with their steric and electrostatic fields. The CoMFA descriptor fields were calculated at 
each lattice with a grid spacing of 1 Å and extending to 4 Å units in all three dimensions within the 
defined region [20]. The Van Der Waals potentials and Coulombic terms, which represent steric and 
electrostatic fields, respectively, were calculated by using the standard Tripos force field. In the 
CoMFA method, a sp
3 hybridized carbon atom with a charge of 1e was used as a probe atom, the 
energy values of the steric and electrostatic fields were truncated at 30 kcal/mol [21]. 
The steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor CoMSIA 
potential fields were calculated at each lattice intersection of a regularly spaced grid of 1 Å and 
extending to 4 Å using a probe atom with radius 1.0 Å, +1.0 charge, and hydrophobic and hydrogen 
bond properties of +1. The attenuation factor was set to the default value of 0.3 [22]. 
2.4. Regression Analysis and Models Validation 
The partial least-squares (PLS) approach, an extension of multiple regression analysis, was applied 
to linearly correlate the CoMFA and CoMSIA fields to the pIC50 values. CoMFA and CoMSIA 
descriptors were used as the independent variables. Column filtering was used at the default value of 
2.0 kcal/mol in the cross-validation part. 
The cross-validation analysis was performed using the leave-one-out (LOO) method in which one 
molecule was omitted from the dataset. The activity of the omitted molecule was then predicted by 
using the model derived from the rest of the dataset [23]. The leave-one-out (LOO) cross-validation 
method could check the predictivity of the obtained model and identify the optimum number of 
components (ONC). Thus, the optimum number of components (ONC) was the number of components 
that led to the highest cross-validated correlated correlation coefficient r
2 ( r
2
cv) [24]. Finally, the 
CoMFA and CoMSIA models were generated using non-cross-validated PLS analysis with the 
optimum number of components (ONC) determined by the cross-validation. 
2.5. Predictive Correlation Co-efficient (r
2
pred) 
The predictive abilities of 3D-QSAR models were validated by predicting the activities of a test set 
of 10 compounds that were not included in the training set. These molecules were aligned to the 
template and their pIC50 values were predicted by the produced models which were obtained using the 
training set. The predictive correlation coefficient (r
2
pred), based on the molecules of the test set, was 
calculated using Equation (2):   
r
2
pred =   ( S D - P R E S S ) / S D               ( 2 )  Int. J. Mol. Sci. 2011, 12 
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In this equation, SD is the sum of the squared deviations between the inhibitory activities of the test 
set and the mean activity of the training molecules and PRESS is the sum of squared deviations 
between predicted and actual activity values for each molecule in the test set [25]. 
2.6. Molecular Docking 
The Surflex-Dock was applied to study molecular docking by using an empirical scoring function 
and a patented search engine to dock ligands into a protein’s binding site [16]. The crystal structure of 
Aurora A was retrieved from the RCSB Protein Data Bank (PDB entry code: 2X6E). The ligands were 
docked into corresponding protein’s binding site by an empirical scoring function and a patented 
search engine in Surflex-Dock [16]. All ligands and water molecules in Aurora A 2X6E have been 
deleted and the polar hydrogen atoms were added to 2X6E. Protomol, a representation of a ligand 
making every potential interaction with the binding site, was applied to guide molecular docking. 
Protomols could be established by three manners: (1) Automatic: Surflex-Dock finds the largest cavity 
in the receptor protein; (2) Ligand: a ligand in the same coordinate space as the receptor; (3) Residues: 
specified residues in the receptor [26,27].   
In this paper, the automatic docking was applied. The Aurora A structure was utilized in subsequent 
docking experiments without energy minimization. Other parameters were established by default in the 
software. Surflex-Dock scores (total scores) were expressed in –log10(Kd) units to represent binding 
affinities. Then, the MOLCAD (Molecular Computer Aided Design) program was employed to 
visualize the binding mode between the protein and ligand. MOLCAD calculates and exhibits the 
surfaces of channels and cavities, as well as the separating surface between protein subunits [20–22]. 
MOLCAD program provides several types to create a molecular surface [16]. The fast Connolly 
method using a marching cube algorithm to engender the surface was applied in this work, thus the 
MOLECAD Robbin and Multi-Channel surfaces program exhibited with copious potentials were 
established. Moreover, Surflex-Dock total scores, which were expressed in –log10(Kd) units to 
represent binding affinities, were applied to estimate the ligand-receptor interactions of newly 
designed molecules. 
3. Results and Discussions 
3.1. CoMFA and CoMSIA Models 
The statistical parameters for the CoMFA and CoMSIA models are given in Table 3. For the 
CoMFA model, partial least squares (PLS) regression produced a excellent cross-validated correlation 
coefficient (r
2
cv) of 0.726 (>0.5) with an optimized component of 6, which suggesting that the model is 
reliable and it should be a useful tool for predicting the IC50 values. The non cross-validated PLS 
analysis gave a high correlation coefficient (r
2) of 0.972, F value of 105.300 and a low standard error 
estimate (SEE) of 0.144. The contributions of steric and electrostatic fields to this model were 0.457 
and 0.543, respectively. The predictive correlation coefficient (r
2
pred) value based on molecules of the 
test set was 0.937 for the CoMFA model. The actual and predicted pIC50 values of the training set and 
test set by the model are given in Table 2. The relationship between actual and predicted pIC50 of the  
 Int. J. Mol. Sci. 2011, 12 
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training set and test set compounds of the CoMFA model is illustrated in Figure 3a, where almost all 
points are located on the diagonal line.   
Table 3. Results of CoMFA and CoMSIA models. 
Statistics CoMFA CoMSIA 
r
2
cv
a 0.726  0.566 
r
2b 0.972  0.984 
ONC
c 6  6 
SEE
d 0.144 0.110 
F value
e 105.300 181.398 
r
2
pred
f 0.937 0.948 
Field contribution     
Steric 0.457 0.152 
Electrostatic 0.543  0.169 
Hydrophobic -  0.243 
H-bond Donor  -  0.183 
H-bond Acceptor  -  0.252 
a cross-validated correlation coefficient; 
b non-cross-validated coefficient; 
c optimal number 
of components; 
d standard error of estimate; 
e value F-test value; 
f predictive correlation 
coefficient. 
Figure 3. Graph of actual versus predicted pIC50 of the training set and the test set using 
CoMFA (a) and CoMSIA (b). 
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For the CoMSIA model, the statistical parameters revealed that steric, electrostatic, hydrophobic, 
hydrogen bond donor and acceptor features significantly influence the activity of the inhibitors. The 
CoMSIA model gave a cross-validated correlation coefficient (r
2
cv) of 0.566 (>0.5) with an optimized 
component of 6, which suggested that the model is reliable and should be a useful tool for predicting 
the IC50 values. The non cross-validated PLS analysis gave a high correlation coefficient (r
2) of 0.984, 
F value of 181.398 and a low error estimate (SEE) of 0.110. The contributions of steric, electrostatic, Int. J. Mol. Sci. 2011, 12 
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hydrophobic, hydrogen bond donor and acceptor fields were 0.152, 0.169, 0.243, 0.183 and 0.252, 
respectively. The predictive correlation coefficient (r
2
pred) value based on molecules of the test set was 
0.948 for the CoMSIA model. The actual and predicted pIC50 values and residual values for training 
set and test set compounds are given in Table 2. The graph of actual activity versus predicted pIC50 of 
the training set and test set is illustrated in Figure 3b, where almost all points are located on the 
diagonal line. 
3.2. CoMFA and CoMSIA Contour Maps 
The results of the CoMFA and CoMSIA models were visualized through contour maps. These maps 
showed regions in 3D space where variation in specific molecular properties increased or decreased 
the activity. The molecular fields around the most active compound 20 are displayed in Figures 4–6, 
accordingly. These contour maps are significant for drug design, as they showed regions in 3D space 
where modifications of the molecular fields strongly correlated with concomitant changes in  
biological activity. 
The steric contour map of CoMFA is shown in Figure 4a, which was almost the same as the 
corresponding CoMSIA steric contour map (Figure 4b). Compound 20 was selected as a reference 
molecule. The steric field was represented by green and yellow contours, in which green contours 
indicate regions where presence of bulky steric groups was favored and should enhance inhibitory 
activity of molecules, while the yellow contours represent regions where occupancy of steric groups 
was unfavorable. As shown in Figure 4, the presence of the green contour around the R
1 position 
suggested that a bulky group at this region would be favorable. By checking up all the R
1  
modified compounds, it was found that derivatives 07–08 have the activity order of 07 (R
1 = Br) >  
08 (R
1 = NO2); compounds 13,  14,  17 have the activity order of 14 (R
1 = -SO2CH2CHCH2) >  
13 (R
1 = -SO2C2H5) > 17 (R
1 = -SO2NH2); compounds 17–19 have the activity order of  
20 (R
1 = sulfo-pyrrolidine) > 19 (R
1 = -SO2N(CH3)2) > 18 (R
1 = -SO2NHCH3) > 17 (R
1 = -SO2NH2); 
compounds 23–26 have the activity order of 23 (R
1 = -NHSO2C2H5) < 24 (R
1 = -NHSO2-benzene),  
25 (R
1 = -NHSO2-CH2-benzene) < 26 (R
1 = -NHSO2-benzene). These were satisfactory according to 
the steric contour map. The R
2 was surrounded by three yellow contours, which suggested a bulky 
group at this region would decrease the inhibitory activity. This may explain why compounds 1–2, 5, 
which possessed a relative bulky group (e.g., -COOEt) at R
1, showed significantly decreased activities 
than other compounds with a relatively minor substituent at R
2. For instance, derivative 24 bearing a 
carboxy group at R
2 exhibited improved potency than compound 26 with an ethoxycarbonyl at this 
position. Furthermore, compound 20 with carboxyl group at the R
2 position was the most  
inactive compound. 
The electrostatic field contour maps of CoMFA and CoMSIA are shown in Figure 5a and b, 
respectively. Compound 20 was selected as a reference molecule again. The electrostatic field is 
indicated by blue and red contours, which demonstrate the regions where electron-donating group and 
electron-withdrawing group would be favorable, respectively. In the electrostatic field, two blue 
contours around the terminal of R
1 and two red contours at the middle of the R
1 revealed that the 
electron-donating substituents at the terminal of the R
1 and the electron-withdrawing groups at the 
middle of the R
1 were essential for the inhibitory activity. Take the compounds 13–22 and 24–26  Int. J. Mol. Sci. 2011, 12 
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(R
1 = 4-CF3-benzyl) for an example, the strong electron-withdrawing sulfo, and sulfanilamido group at 
the middle of R
1 and electron-donating Et, -NH2, -NHCH3, -N(CH3)2, 1-pyrrolidine, 1-piperidine, and 
4-morpholine groups at the terminal of R
1 in these compounds resulted in significantly increased 
activity. The blue contour near the chain between 6,7-dihydro-1H-inden-4(5H)-one and R
2 suggested 
the electron-donating group (-CH2CH2-) at this position may be essential for potency. All of the 
derivatives involved in this study possessed a -CH2CH2- group at this site, which revealed the extreme 
importance of the electron-donating substituent. 
Figure 4. Contour maps of CoMFA (a) and CoMSIA (b) analysis in combination with 
compound  20.  Steric fields: green contours (80% contribution) indicate regions where 
bulky groups increase activity, while yellow contours (20% contribution) indicate regions 
where bulky groups decrease activity. Compound 20 is depicted in ball and stick 
representation, colored by atom type (white C, blue N, red O, cyan H). 
( a )                    ( b )  
   
Figure 5. Contour maps of CoMFA (a) and CoMSIA (b) analysis in combination with 
compound  20.  Electrostatic fields: blue contours (80% contribution) represent regions 
where electron-donating groups increase activity, while red contours (20% contribution) 
represent regions where electron-withdrawing groups increase activity. Compound 20 is 
depicted in ball and stick representation, colored by atom type (white C, blue N, red O, 
cyan H). 
(a)  (b) 
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In hydrophobic fields, yellow and white contours highlighted areas where hydrophobic and 
hydrophilic properties were favored. In Figure 6a, the yellow contour around the chain of R
1 position 
indicated that a hydrophobic substituent would benefit the potency. Most of the derivatives involved in 
this study possessed a hydrophobic group at this site, which revealed the extreme importance of the 
hydrophobic substituent. Furthermore, the actual IC50 of these compounds was basically 10-fold than 
those without a hydrophobic group. A huge white contour near the terminal of R
1 site suggested that a 
hydrophilic group may be favored. This may explain why derivative 20 with a relatively more 
hydrophilic N atom at this position exhibited better potencies than compounds 25–33. Another white 
contour around R
2 position demonstrated that a hydrophilic substituent carboxyl would be favorable. 
Most of the compounds possessed a hydrophilic substituent at this site, except compounds 1–2 with a 
hydrophobic -OOC2H5 at R
2,
 which displayed lower activity than compounds 3–25. 
Figure 6. Contour maps of CoMSIA analysis in combination with compound 20. 
Hydrophobic fields (a), the yellow and white contours (80% and 20% contributions) 
indicate favorable and unfavorable hydrophobic groups; Hydrogen bond donor contour 
map (b), the cyan and purple contours (80% and 20% contributions) indicate favorable and 
unfavorable hydrogen bond donor groups; Hydrogen bond acceptor contour map (c), the 
magenta and red contours (50% and 50% contributions) indicate favorable and unfavorable 
hydrogen bond acceptor groups. Compound 20 is depicted in ball and stick representation, 
colored by atom type (white C, blue N, red O, cyan H). 
(a)         ( b )  
   
(c) 
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In hydrogen bond donor field, the cyan and purple contours indicated favorable and unfavorable 
hydrogen bond donor groups. In Figure 6b, the two bulk purple contours near the R
1 position revealed 
that hydrogen bond acceptor groups may benefit the potency. In fact the sulfo group and quaternary 
amine atom at this position acted as hydrogen bond acceptor by forming H-bonds with residues of the 
ATP binding site of Aurora A. This may explain why compounds 19–22 displayed relatively better 
activities. Likewise, a bulk purple contour near R
2 revealed that they acted as hydrogen bond acceptor 
by forming H-bonds with residues of the ATP binding site of Aurora A. Most of the derivatives 
involved in this study possessed a hydrogen bond acceptor group (carboxyl) at this site, which 
indicated the extreme importance of the hydrogen bond acceptor group substituent.   
In hydrogen bond acceptor field, the magenta and red contours identified favorable and unfavorable 
positions for hydrogen bond acceptors. In Figure 6c, two bulk red contours around the R
1 and R
2 
indicated that a hydrogen bond acceptor substituent at these sites would increase the activity. The 
inference obtained by Figure 6c satisfactorily matched the hydrogen bond donor contour map.   
3.3. Docking Analysis 
Surflex-Dock was applied to investigate the binding mode between these pyrrole-indoline-2-ones 
and Aurora A. In this paper, Surflex-Dock could also serve to inspect the stability of 3D-QSAR models 
previous established. To visualize secondary structure elements, the MOLCAD Robbin surfaces 
program was applied. Furthermore, the MOLCAD surface of ATP site was also developed and 
displayed with cavity depth (CD), electrostatic potential (EP) to further explore the interaction between 
these inhibitors and the receptor. The most potent inhibitor 20 was selected for more   
detailed research. 
In Figure 7a, the hydrogen bonding (dashed lines) interactions between the reference compound 20 
with highest inhibitory activity is shown and the key residues (Lys162, Asp274, Glu211, and Arg220) 
of the ATP site of Aurora A (PDB code 2X6E) are labeled. A total of five hydrogen bonds were formed: 
the sulfo at R
1 position acted as the hydrogen bond acceptor and formed two H-bonds with the 
secondary amino group of the Tys162 residue, and a H-bond with the secondary amino group of 
Asp274; the carbonyl substituent on the 6,7-dihydro-1H-inden-4(5H)-one scaffold in compound 20 
also acted as the hydrogen bond acceptor and formed H-bond with primary amino group of Arg220 
residue; the secondary amino on the 6,7-dihydro-1H-inden-4(5H)-one in compound 20  acted as 
H-bond donor and formed H-bond with carbonyl group of Glu211. These results observed by Figure 
7a satisfactorily matched the observation taken from the CoMSIA hydrogen bond donor contour map. 
In Figure 7b, the secondary structure of the ATP pocket within compound 20 is depicted: alpha 
helices are displayed as helices or cylinders, while beta sheets are shown as arrows and the loop 
regions as tubes. The key residues and hydrogen bonds (dashed lines) are labeled. 
In Figure 7c, the MOLCAD Multi-Channel cavity depth potential surfaces structure of the binding 
site within the compound 20 is displayed and the cavity depth color ramp ranged from blue (low depth 
values = outside of the pocket) to light red (high depth values = cavities deep inside the pocket). In 
Figure 7c, the R
1 position of compound 20 is observed in a blue area, revealing that this position was 
embedded deep inside the ATP pocket. It can be simply inferred that a bulky group at R
1 position may 
be favorable. Since the R
2 site was oriented to a light red area, which illustrated a minor group was Int. J. Mol. Sci. 2011, 12 
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anchored into a favorable region, this suggests that minor groups may benefit the potency. The 
observation obtained by Figure 7c satisfactorily matched the corresponding CoMFA and CoMSIA 
steric contour maps. 
Figure 7. Docked binding modes of compound 20 in the ATP binding site of Aurora A 
(PDB code 2X6E). In each panel, compound 20 is shown as ball and stick representation; 
hydrogen bonds are shown as dashed yellow line; residues are shown as line representation. 
(a) Key residues (additional residues) and hydrogen bonds are distinctly labeled; (b) the 
MOLCAD ribbon surfaces: Alpha helices are shown as helices or cylinders; beta sheets are 
shown as arrows; the loop regions as tubes; key residues and hydrogen bonds are labeled; 
(c) The MOLCAD cavity depth potential surface: cavity depth color ramp ranges from blue 
(low depth values = outside of the pocket) to light red (high depth values = cavities deep 
inside the pocket); (d) The MOLCAD electrostatic potential surface: the color ramp for EP 
ranges from red (most positive) to purple (most negative). 
(a)               (c) 
   
(b)           (d) 
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In Figure 7d, the MOLCAD electrostatic potential surface of the binding region was demonstrated 
with the color ramp for EP ranging from red (most positive) to purple (most negative). The 
1-pyrrolidinyl group at the terminal of R
1 was found in a blue area, which indicated that 
electron-donating properties at this site were essential for the potency; the sulfo group was in a yellow 
area, which suggested that electron-withdrawing properties would be favored; the -CH2CH2- chain 
between 6,7-dihydro-1H-inden-4(5H)-one and carboxyl was anchored in a blue area which suggested 
that an electron-donating substituent at this position would be essential for the potency. These results 
were well compared with the corresponding CoMFA and CoMSIA electrostatic contour maps. 
3.4. Design for New Molecules 
The detailed contour map analysis of both COMFA and CoMSIA models and the docking analysis 
empowered us to identify structural requirements for the observed inhibitory activity (Figure 8). In 
detail, bulky, electron-donating, hydrophobic, and hydrogen bond acceptor substituents at the terminal 
of R
1 (e.g., pyrrolidine) would increase activity; bulky, electron-withdrawing, hydrophilic, and 
hydrogen bond acceptor substituents at the chain of the R
1 (e.g., sulfo group) are favored for inhibitory 
activity; minor, hydrophilic, hydrogen bond donor groups at the R
2 (e.g., carboxyl) may benefit 
potency. Moreover, the electron-donating chain (-CH2CH2-) between pyrrole and R
2 may be essential 
for the activity of the inhibitors. The chain of the R
1, indolin-2-one, and 
6,7-dihydro-1H-indol-4(5H)-one groups were crucial for binding to ATP pocket of Aurora A. 
Based on QSAR and docking results, inhibitor 20, with the highest activity, was taken as a template 
to design new compounds. A set of nine new compounds with high predicted activity were designed 
and assessed (Table 4), and the graphs of their predicted pIC50 values versus the most active compound 
20 are shown in Figure 9. After energy minimization, the nine new compounds were docked into the 
ATP binding site of Aurora A. The total scores of these compounds were higher than that of the 
template molecule (Table 4). The designed molecule D8 was selected for more detailed investigation 
as one more H-bond from carbonyl on indolin-2-one group with Ala213 can be observed in Figure 10, 
where the compound D8 with the highest surflex-dock total score were docked into the ATP pocket of 
Aurora A.   
Table 4. Structure, predicted pIC50 values, and surflex-dock total score of the newly 
designed molecules. 
N
H
O
O2
S
N
H
O HOOC
N R1
R2
 
Compound 
NO. 
Substituent Predicted  pIC50 
Total 
score  R
1 R
2 
CoMF
A 
CoMSI
A 
20  H H  8.073  8.049  8.49 
D1  H C(CH3)3 7.822  8.095  9.09 Int. J. Mol. Sci. 2011, 12 
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Table 4. Cont. 
D2  H CH2C(CH3)3 7.823  8.133  10.28 
D3  H CH2CH2C(CH3)3 8.044  8.302  9.82 
D4  CH3 CH3 8.047  8.294  8.91 
D5  H CH3 8.091  8.203  7.60 
D6  CH3 CH2CH3 7.710  8.160  8.88 
D7  CH2CH3 CH2CH3 7.661  8.156  9.23 
D8  CH2CH2CH3 CH2CH2CH3 7.647  8.145  10.46 
D9  CH3 cyclohexane  7.633  8.154  10.32 
Figure 8. Structure-activity relationship revealed by present studies. 
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Bulky, electron-donating, hydrophobic, and hydrogen
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Hydrogen bond binding region
Hydrogen bond binding region
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Figure  9. Predicted pIC50 values of newly designed molecules using CoMFA and 
CoMSIA. 
20 D1 D2 D3 D4 D5 D6 D7 D8 D9
7.6
7.7
7.8
7.9
8.0
8.1
8.2
8.3
P
r
e
d
i
c
t
e
d
 
p
I
C
5
0
b
y
 
C
o
M
F
A
 
a
n
d
 
C
o
M
S
I
A
Molecule
 CoMFA
 CoMSIA
 Int. J. Mol. Sci. 2011, 12 
 
1621
Figure 10. Docked binding modes of compound D8 in the ATP binding site of Aurora A. 
Compound  D8 is shown as stick representation; hydrogen bonds are shown as dashed 
yellow lines; residues are shown as line representation.  (a) Key residues (additional 
residues) and hydrogen bonds are distinctly labeled. (b) Alpha helices are shown as helices 
or cylinders; beta sheets are shown as arrows; the loop regions as tubes; key residues and 
hydrogen bonds are labeled. 
(a) 
 
(b) 
 
4. Conclusion 
We employed 3D-QSAR and docking methods to explore the structure-activity relationship of a 
series of pyrrole-indoline-2-ones as Aurora inhibitors. The 3D-QSAR models described herein Int. J. Mol. Sci. 2011, 12 
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possessed excellent consistency. The predictive ability of the models were manifested in the good 
correlation between actual and predicted pIC50  values for the test molecules. The CoMFA and 
CoMSIA contour maps as well as the docking results provided enough information to understand the 
structure-activity relationship, identify structural features influencing the inhibitory activity, and 
furthermore, design new molecules. A number of novel pyrrole-indoline-2-ones derivatives were 
designed by using the SAR taken from the present study. The predicted activities of these newly 
designed pyrrole-indoline-2-ones may be reliable. The correlation of the results obtained from 
3D-QSAR and docking studies can serve as a useful guideline for the further modification of 
pyrrole-indoline-2-ones that function as Aurora A inhibitors. 
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